Gliosarcoma
Drug research and approvals for gliosarcoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 13 studies of gliosarcoma are recruiting on ClinicalTrials.gov, and Health Canada has authorized 1 drug trials for it since 2013.
- Recruiting worldwide: 13
- Trials authorized in Canada: 1
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 13 recruiting on ClinicalTrials.gov ↗- GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma…NCT07301268 · Phase 2 · Mayo Clinic · starts Aug 3, 2026
- ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV…NCT07089641 · Phase 1 · Jonsson Comprehensive Cancer Center · starts Jul 28, 2025
- A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the…NCT07134842 · Phase 1 · University College, London · starts Jul 10, 2025
- Study of ABBV-637 or ABBV-155 With ERAS-801 for People With GlioblastomaNCT06934889 · Phase 1 · Memorial Sloan Kettering Cancer Center · starts Apr 7, 2025
- Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain TissueNCT05756985 · Not reported · Baptist Health South Florida · starts Dec 11, 2024
- A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent GliomaNCT05698524 · Phase 1 · University of Nebraska · starts Jun 26, 2023
- Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational StudyNCT06954636 · Not reported · Sied Kebir · starts May 3, 2023
- Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBMNCT04991870 · Phase 1 · M.D. Anderson Cancer Center · starts Apr 28, 2023
- Ex Vivo Drug Sensitivity Testing and Multi-Omics ProfilingNCT05857969 · Phase 1 · Florida International University · starts Feb 22, 2023
- hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)NCT05052957 · Phase 2 · Leland Metheny · starts Jan 20, 2023
Drug Pipeline
5 in phase 3, 51 in phase 2, 46 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition- Temozolomide
- Phase 3 DNA inhibitor
- Bevacizumab
- Phase 3 Vascular endothelial growth factor A inhibitor
- Lomustine
- Phase 3 DNA inhibitor
- Rindopepimut
- Phase 3 Epidermal growth factor receptor erbB1 vaccine antigen
- Depatuxizumab mafodotin
- Phase 3 Epidermal growth factor receptor erbB1 binding agent
- Erlotinib
- Phase 2 Epidermal growth factor receptor erbB1 inhibitor
- Temsirolimus
- Phase 2 FK506-binding protein 1A inhibitor
- Vorinostat
- Phase 2 Histone deacetylase 1 inhibitor
- Hydroxyurea
- Phase 2 Ribonucleoside-diphosphate reductase RR1 inhibitor
- Irinotecan
- Phase 2 DNA topoisomerase I inhibitor
- Sorafenib
- Phase 2 Serine/threonine-protein kinase RAF inhibitor
- Carmustine
- Phase 2 Glutathione reductase inhibitor
- Pembrolizumab
- Phase 2 Programmed cell death protein 1 inhibitor
- Nivolumab
- Phase 2 Programmed cell death protein 1 inhibitor
- Cediranib
- Phase 2 Stem cell growth factor receptor inhibitor
- Tipifarnib
- Phase 2 Protein farnesyltransferase inhibitor
- Cilengitide
- Phase 2 Integrin alpha-V/beta-3 antagonist
- Topotecan
- Phase 2 DNA topoisomerase I inhibitor
- Vandetanib
- Phase 2 Tyrosine-protein kinase SRC inhibitor
- Ipilimumab
- Phase 2 Cytotoxic T-lymphocyte protein 4 inhibitor
- Bortezomib
- Phase 2 26S proteasome inhibitor
- Cyclophosphamide anhydrous
- Phase 2 DNA inhibitor
- Guanine
- Phase 2
- Carboplatin
- Phase 2 DNA inhibitor
- Pazopanib
- Phase 2 Macrophage colony stimulating factor receptor inhibitor
- Aflibercept
- Phase 2 Vascular endothelial growth factor A inhibitor
- Gefitinib
- Phase 2 Epidermal growth factor receptor erbB1 inhibitor
- Dasatinib anhydrous
- Phase 2 Tyrosine-protein kinase ABL inhibitor
- Imatinib
- Phase 2 Tyrosine-protein kinase ABL inhibitor
- Filgrastim
- Phase 2 Granulocyte colony stimulating factor receptor agonist
Showing the 30 furthest along of 102 in trials.
How Its Trials Ended
236 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 88 whose ending is known, 15% met their primary endpoint, 24% missed it and 61% stopped early.
- Completed, result not reported10344%
- Ongoing4017%
- Missed its primary endpoint219%
- Stopped: other or unclear208%
- Met its primary endpoint136%
- Stopped: enrollment or feasibility136%
- Stopped: sponsor or business decision115%
- Status unknown52%
- Stopped: lack of efficacy42%
- Stopped: funding42%
- Stopped: safety21%
Trials Authorized in Canada
Newest first; search them all in Canada trials| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Aug 8, 2016 | A phase II, multi-center, open-label study of a conditionally replicative adenovirus (dnx-2401) with pembrolizumab (keytruda) for recurrent glioblastoma or…DNX-2401 / keytruda | Dnatrix, Inc | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA